

# OUTCOMES THAT OUTPERFORM

Across 15 years of U.S. Medicare claims data,<sup>1,2</sup> long-term reintervention and rupture rates were lowest in patients treated with the GORE® EXCLUDER® Device.<sup>3</sup>

The long-term follow-up:  
**VQI-VISION® dataset**

20,489

EVAR patients


282

U.S. centers


> 40%

with the EXCLUDER®  
Device

**Reintervention Rate**



**Late AAA Rupture Rate**



For more information on  
this unique surveillance  
study, access the full  
published results and  
appendix today.



Full publication



Appendix

Images courtesy of British Medical Journal Publishing Group. Used with permission.

Across all endografts, mortality was similar within the first decade after EVAR.

\* VQI-VISION, Vascular Quality Initiative - Vascular Implant Surveillance and Interventional Outcomes Network.

COOK and ZENITH are trademarks of Cook Medical, Inc. ENDOLOGIX and AFX are trademarks of Endologix LLC. MEDTRONIC and ENDURANT are trademarks of Medtronic, Inc.

See reverse side for references and product indications.

Together, improving life



## References

1. Hoel AW, Faerber AE, Moore KO, *et al.* A pilot study for long-term outcome assessment after aortic aneurysm repair using Vascular Quality Initiative data matched to Medicare claims. *Journal of Vascular Surgery* 2017;66(3):751-759.e1
2. Centers for Medicare & Medicaid Services (CMS). Accessed March 17, 2017. <https://www.cms.gov/>
3. Goodney P, Mao J, Jesse Columbo J, *et al*; on behalf of the Society for Vascular Surgery's Patient Safety Organization. Use of linked registry claims data for long term surveillance of devices after endovascular abdominal aortic aneurysm repair: observational surveillance study. *BMJ* 2022;379:e071452



**INDICATIONS FOR USE IN THE U.S.:** The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below: Adequate iliac/femoral access; Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm; Proximal aortic neck angulation  $\leq 60^\circ$ ; Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm. **Aortic Extender and Iliac Extender Endoprosthesis.** The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and/or sealing for aneurysmal exclusion is desired. **CONTRAINDICATIONS:** The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in: patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at [eifu.goremedical.com](http://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. <sup>1</sup> <sub>Only</sub>

Products listed may not be available in all markets.

COOK and ZENITH are trademarks of Cook Medical, Inc. ENDOLOGIX and AFX are trademarks of Endologix LLC. MEDTRONIC and ENDURANT are trademarks of Medtronic, Inc.

GORE, *Together, improving life*, EXCLUDER and designs are trademarks of W. L. Gore & Associates.

© 2023 W. L. Gore & Associates, Inc. 231001804-EN JUNE 2023

W. L. Gore & Associates, Inc.  
[goremedical.com](http://goremedical.com)

Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673  
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

